News articles about Healthequity (NASDAQ:HQY) have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Healthequity earned a news impact score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.7338007744258 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Zacks: Analysts Expect Healthequity Inc (HQY) to Announce $0.07 EPS (americanbankingnews.com)
- Healthequity Inc (HQY) EVP Delano Ladd Sells 26,405 Shares (americanbankingnews.com)
- HealthEquity, Inc. :HQY-US: Earnings Analysis: Q3, 2018 By the Numbers : December 11, 2017 (finance.yahoo.com)
- Cantor Fitzgerald Analysts Reduce Earnings Estimates for Healthequity Inc (HQY) (americanbankingnews.com)
- FY2018 EPS Estimates for Healthequity Inc (HQY) Increased by Analyst (americanbankingnews.com)
Healthequity (HQY) traded up $1.09 during trading hours on Friday, hitting $45.89. The stock had a trading volume of 1,329,341 shares, compared to its average volume of 575,277. Healthequity has a fifty-two week low of $37.62 and a fifty-two week high of $55.31. The company has a market capitalization of $2,780.00, a P/E ratio of 65.56, a price-to-earnings-growth ratio of 1.90 and a beta of 1.74.
A number of brokerages recently issued reports on HQY. BidaskClub downgraded Healthequity from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Cantor Fitzgerald restated a “buy” rating and issued a $56.00 price target on shares of Healthequity in a research report on Tuesday, December 5th. Chardan Capital raised their price target on Healthequity from $58.00 to $62.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. Zacks Investment Research downgraded Healthequity from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Finally, Robert W. Baird restated a “hold” rating on shares of Healthequity in a research report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. Healthequity presently has a consensus rating of “Buy” and a consensus target price of $58.33.
In other news, Director Frank Medici sold 700 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total transaction of $35,735.00. Following the transaction, the director now owns 6,381 shares in the company, valued at $325,750.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 26,405 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $43.32, for a total value of $1,143,864.60. Following the transaction, the executive vice president now owns 16,692 shares in the company, valued at approximately $723,097.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,761,117 shares of company stock valued at $91,904,676. Corporate insiders own 29.00% of the company’s stock.
WARNING: This story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2017/12/17/healthequity-hqy-receives-daily-media-impact-rating-of-0-10.html.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.